NewslettersPancreatic Cell News An EGFR/HER2-Targeted Conjugate Sensitizes Gemcitabine-Sensitive and Resistant Pancreatic Cancer through Different SMAD4-Mediated Mechanisms By Bob - September 27, 2022 0 To overcome chemoresistance in PDAC, researchers aimed to study dual-targeting ligand-based lidamycin efficacy when combined with gemcitabine and exploreed its mechanisms of action. [Nature Communications] Full Article